1.What is intraperitoneal thermal perfusion chemotherapy? The concept of intraperitoneal chemotherapy was introduced by the National Cancer Institute in the United States in 1970 with the use of intraperitoneal injection of chemotherapeutic fluid for the treatment of ascites in advanced ovarian cancer, and after the International Conference on Intraperitoneal Chemotherapy in Los Angeles, USA in 1988, intraperitoneal chemotherapy has become an indispensable tool for cancer treatment. At present, chemotherapeutic fluid at a constant temperature of 42~45℃ is rapidly instilled into the abdominal cavity by pre-implanted chemotherapy pump or laparotomy, and then the patient is asked to change position to distribute the chemotherapeutic fluid evenly. This treatment is called abdominal thermal perfusion chemotherapy. 2.What is the principle of peritoneal thermal perfusion chemotherapy? (1) Tumor cells and normal tissue cells have different temperature tolerance. Normal tissue cells can tolerate 45℃ high temperature, while tumor cells will die at 40℃~43℃. (2) Heating can disrupt the steady state of cell membrane and increase the permeability of cells. (3) Due to the change of permeability, it increases the absorption and permeation of drugs by the cells. (4) Heating can increase the concentration and response rate of the drug in the cell. (5) Heating can change the metabolic mechanism of the drug. (6) Addition of temperature increases the interaction of drugs with DNA or inhibits DNA repair. (7) Peritoneal perfusion can directly increase the concentration of anti-cancer drugs in the peritoneal cavity, reduce the concentration of drugs in the body circulation, increase the local cytotoxic effect of lesions and reduce systemic adverse effects. (8) High concentration of chemotherapeutic drugs can be absorbed into the liver through portal vein, which has strong killing effect on cancer cells metastasized to the liver. (9) Large volume liquid peritoneal perfusion can play a mechanical flushing role and kill free cancer cells in the abdominal cavity. It is based on these principles that high-temperature, hypotonic peritoneal perfusion chemotherapy is used to treat patients after radical surgery for progressive gastrointestinal cancer. 3.What patients are suitable for abdominal thermal perfusion therapy? (1) Post-operative gastrointestinal or gynecological malignancies, killing residual and peritoneal micro-implantation foci. (2) Tumor invasion or invasion of the plasma layer and invasion of the surrounding adjacent tissues. (3) Cancerous ascites or ascites pathology suggesting positive cancer cells. (4) After palliative resection of gastrointestinal tract or gynecological malignancy. (5) Those with N2 lymph node metastasis. (6) Advanced gastrointestinal cancer and gynecologic malignant tumors that are inoperable at the time of diagnosis, and the tumor shrinks with intraperitoneal thermal perfusion chemotherapy, so that the patient can regain the opportunity of surgery. (7) Intra-abdominal recurrence of malignant tumor, metastasis and malignant ascites can inhibit tumor growth, reduce pain and prolong survival.